Ra Capital Management, L.P. - Feb 6, 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
TYRA
Transactions as of
Feb 6, 2024
Transactions value $
$61,387,604
Form type
4
Date filed
2/8/2024, 05:16 PM
Previous filing
Jan 12, 2024
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Award $41.4M +3.18M +60.04% $13.01 8.48M Feb 6, 2024 See footnotes F1, F2
holding TYRA Common Stock 1.5M Feb 6, 2024 See footnotes F2, F3
holding TYRA Common Stock 443K Feb 6, 2024 See footnotes F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Pre-Funded Warrants (Right to Buy) Award $20M +1.54M $13.01 1.54M Feb 6, 2024 Common Stock 1.54M $0.00 See footnotes F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F2 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3 These securities are held directly by the Nexus Fund.
F4 These securities are held directly by the Account.
F5 The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Remarks:

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.